Zacks Research Research Analysts Boost Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research upped their FY2026 earnings per share estimates for shares of Corcept Therapeutics in a research report issued to clients and investors on Wednesday, September 25th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings of $2.11 per share for the year, up from their previous forecast of $2.09. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.12 per share.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.09. The company had revenue of $163.80 million for the quarter, compared to analyst estimates of $155.14 million. Corcept Therapeutics had a net margin of 21.93% and a return on equity of 23.66%. The firm’s quarterly revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.25 EPS.

Several other brokerages also recently weighed in on CORT. HC Wainwright upped their price target on Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Truist Financial reissued a “buy” rating and set a $65.00 price objective on shares of Corcept Therapeutics in a research report on Monday, June 17th. Piper Sandler raised their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $38.00 price target on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $53.75.

Corcept Therapeutics Trading Up 1.5 %

Shares of NASDAQ CORT opened at $43.93 on Monday. The stock has a market cap of $4.57 billion, a P/E ratio of 41.44 and a beta of 0.45. The business’s fifty day simple moving average is $36.39 and its 200-day simple moving average is $30.77. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $44.37.

Insiders Place Their Bets

In related news, insider Gary Charles Robb sold 3,101 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $35.71, for a total transaction of $110,736.71. Following the completion of the sale, the insider now owns 23,190 shares in the company, valued at $828,114.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Corcept Therapeutics news, insider William Guyer sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total value of $353,000.00. Following the completion of the transaction, the insider now owns 6,039 shares in the company, valued at $213,176.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary Charles Robb sold 3,101 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $35.71, for a total value of $110,736.71. Following the transaction, the insider now directly owns 23,190 shares in the company, valued at approximately $828,114.90. The disclosure for this sale can be found here. Insiders sold 23,251 shares of company stock valued at $856,212 in the last ninety days. Insiders own 20.50% of the company’s stock.

Institutional Trading of Corcept Therapeutics

A number of large investors have recently made changes to their positions in CORT. Norges Bank purchased a new stake in Corcept Therapeutics in the 4th quarter valued at $24,603,000. PNC Financial Services Group Inc. raised its holdings in shares of Corcept Therapeutics by 28.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,008 shares of the biotechnology company’s stock valued at $358,000 after buying an additional 2,432 shares during the last quarter. Hsbc Holdings PLC boosted its stake in shares of Corcept Therapeutics by 78.1% during the fourth quarter. Hsbc Holdings PLC now owns 46,429 shares of the biotechnology company’s stock worth $1,511,000 after buying an additional 20,360 shares during the period. Allianz Asset Management GmbH grew its holdings in shares of Corcept Therapeutics by 50.7% during the fourth quarter. Allianz Asset Management GmbH now owns 48,818 shares of the biotechnology company’s stock worth $1,586,000 after buying an additional 16,422 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC increased its position in Corcept Therapeutics by 224.8% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 32,578 shares of the biotechnology company’s stock valued at $1,058,000 after acquiring an additional 22,548 shares during the period. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.